Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of acute myeloid leukaemia in younger patients
Autore:
Burnett, AK;
Indirizzi:
Univ Wales Coll Med, Dept Haematol, Cardiff CF14 4XN, S Glam, Wales Univ Wales Coll Med Cardiff S Glam Wales CF14 4XN CF14 4XN, S Glam, Wales
Titolo Testata:
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
fascicolo: 1, volume: 14, anno: 2001,
pagine: 95 - 118
SICI:
1521-6926(200103)14:1<95:TOAMLI>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MARROW TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; TRIAL COMPARING IDARUBICIN; DOSE CYTOSINE-ARABINOSIDE; MINIMAL RESIDUAL DISEASE; POLYMERASE-CHAIN-REACTION; UNTREATED ADULT PATIENTS; FIRST COMPLETE REMISSION;
Keywords:
consolidation; risk group; allograft; autograft;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
80
Recensione:
Indirizzi per estratti:
Indirizzo: Burnett, AK Univ Wales Coll Med, Dept Haematol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales Univ Wales Coll Med Heath Pk Cardiff S Glam Wales CF14 4XN les
Citazione:
A.K. Burnett, "Treatment of acute myeloid leukaemia in younger patients", BEST P R C, 14(1), 2001, pp. 95-118

Abstract

The survival of AML in younger patients has improved in the last 20 years,as a consequence of a more intensive approach to treatment. Seventy-five to eighty percent of patients will enter complete remission, so the main challenge is to prevent relapse. Several trials have assessed the value of allogeneic or autologous transplantation. When these trials have been assessedby careful statistical methods, the advantage of transplant overall is difficult to detect. Intensive consolidation can deliver a similar survival, of which high-dose Ara-C has been widely adopted, but other intensive schedules appear equivalent. It is not known how many treatment courses are required. Patients are at differing risks of relapse which may influence the choice of treatment. In trials where a risk profile is available, and where a donor versus no-donor analysis is performed, there appears to be little robust evidence to support transplant in good or poor risk disease, although the experience in the latter groups is not unanimous. Standard risk patientsmay be the subgroup who deliver survival benefit, but since chemotherapy continues to improve, there remains some uncertainty. It is possible that technical improvements in transplantation, such as peripheral blood as a source of stem cells, may remove this uncertainty.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:57:30